The New Pharma/Managed Care Relationship in the Age of Value and Consolidation

Are your approaches to marketing strategies for your drug pipeline aligned with payor expectations of value?

HRA’s research has refined the approach to understanding what is valuable to key payor customers – how to meet and exceed expectations in light of the new value-based paradigms in the healthcare industry.

HRA evaluates all important issues and how healthcare companies can meet payor expectations, earning greater clout and establishing stronger relationships with your most important stakeholders.


Product Features:

·         Robust exploration of key topics with desk research, qualitative and quantitative research, and  thought leader perspectives
·         Inclusion of key decision-makers at major managed care payors and Integrated Health Systems
·         Full report, featuring executive summary  & detailed findings 



TOOL Applications
If it is the 'new normal,' what are payor expectations of pharma? Where is pharma succeeding and falling short?
What are the best practices that pharma can or should follow involving value-based contracting? What defines a win-win scenario to contain costs and maximize clinical value?
What can manufacturers of launch products do to compete in the absence of real-world outcomes to win over payors? And what is the ROI for inline brands to consider post-launch studies?
ExpressScripts' move back to a closed formulary model was a game-changer; signaling an invitation to payors to tighten formulary controls, enhance restrictiveness, and to demand more from pharma. How can pharma mitigate this threat?